Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Capital Expenditures (2017 - 2020)

VYNE Therapeutics' Capital Expenditures history spans 4 years, with the latest figure at $71000.0 for Q2 2020.

  • For Q2 2020, Capital Expenditures fell 77.53% year-over-year to $71000.0; the TTM value through Mar 2021 reached $71000.0, down 92.62%, while the annual FY2024 figure was $117000.0, N/A changed from the prior year.
  • Capital Expenditures reached $71000.0 in Q2 2020 per VYNE's latest filing, up from $42000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $449000.0 in Q4 2018 to a low of $12000.0 in Q4 2017.
  • Average Capital Expenditures over 4 years is $204000.0, with a median of $167500.0 recorded in 2019.
  • Peak YoY movement for Capital Expenditures: skyrocketed 3641.67% in 2018, then plummeted 77.53% in 2020.
  • A 4-year view of Capital Expenditures shows it stood at $12000.0 in 2017, then surged by 3641.67% to $449000.0 in 2018, then crashed by 56.12% to $197000.0 in 2019, then plummeted by 63.96% to $71000.0 in 2020.
  • Per Business Quant, the three most recent readings for VYNE's Capital Expenditures are $71000.0 (Q2 2020), $42000.0 (Q1 2020), and $197000.0 (Q4 2019).